Perfluorohexyloctane

Prescription

الأسماء التجارية: MIEBO

الشكل الصيدلاني

Drops

طريق الإعطاء

OPHTHALMIC

الشركة المصنِّعة

Bausch & Lomb Incorporated

About This Medication

11 DESCRIPTION MIEBO ® (perfluorohexyloctane ophthalmic solution) is a sterile, clear and colorless liquid containing 100% perfluorohexyloctane, for topical ophthalmic use. The active ingredient is 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane and is a semifluorinated alkane. It has a molecular formula of C 14 H 17 F 13 and a molecular weight of 432.26 g/mol. The chemical structure is: Perfluorohexyloctane is practically immiscible with water. It is miscible with ethanol and most organic solvents. Each multiple-dose bottle contains 3 mL of perfluorohexyloctane, 1.338 g/mL as a clear and colorless liquid. A structure of a chemical formula AI-generated content may be incorrect.

المواد الفعالة

المادة الفعالة	التركيز
Perfluorohexyloctane	-

المؤشرات العلاجية والاستخدام

1 INDICATIONS AND USAGE MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease. ( 1 )

آلية العمل

12.1 Mechanism of Action Perfluorohexyloctane, a semifluorinated alkane, contains 6 perfluorinated carbon atoms and 8 hydrogenated carbon atoms. Perfluorohexyloctane forms a monolayer at the air-liquid interface of the tear film which can be expected to reduce evaporation. The exact mechanism of action for MIEBO in DED is not known.

الجرعة وطريقة الإعطاء

2 DOSAGE AND ADMINISTRATION Instill one drop of MIEBO four times daily into each eye. ( 2.1 ) 2.1 Recommended Dosage Instill one drop of MIEBO four times daily into affected eye(s). Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO. 2.2 Administration Instructions Step 1. Remove the cap from eye drop bottle. Step 2. Holding the bottle upright, gently squeeze the bottle. Step 3. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle). Step 4. Keeping the bottle upside down, place the bottle above your eye and squeeze it again to release a drop into your eye. Repeat steps 1 - 4 for the second affected eye. Step 2. Step 3. Step 4.

Side Effects Overview

6 ADVERSE REACTIONS Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients with DED, 614 patients received at least one dose of MIEBO in two randomized controlled clinical trials across 68 sites in the United States. The most common ocular adverse reaction was blurred vision. Blurred vision and conjunctival redness were reported in 1-3% of individuals. In four premarketing studies (three open-label [n=127], one randomized [n=24 treated with at least one dose of perfluorohexyloctane]) the most common adverse reaction was hypersensitivity.

التحذيرات والاحتياطات

5 WARNINGS AND PRECAUTIONS 5.1 Use with Contact Lenses MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO.

موانع الاستعمال

4 CONTRAINDICATIONS Hypersensitivity. ( 4.1 ) 4.1 Hypersensitivity MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane [see Adverse Reactions ( 6.1 )] .

الحرائك الدوائية

12.3 Pharmacokinetics The pharmacokinetics of perfluorohexyloctane following topical ocular administration of MIEBO has not been quantitatively characterized in humans. A single pharmacokinetic (PK) study was conducted that showed low systemic perfluorohexyloctane blood levels after topical ocular administration. Perfluorohexyloctane was not metabolized by human liver microsomes in vitro.

Frequently Asked Questions

1 INDICATIONS AND USAGE MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO (perfluorohexyloctane ophthalmic solution) is a semifluorinated alkane indicated for treatment of the signs and symptoms of dry eye disease. ( 1 )

2 DOSAGE AND ADMINISTRATION Instill one drop of MIEBO four times daily into each eye. ( 2.1 ) 2.1 Recommended Dosage Instill one drop of MIEBO four times daily into affected eye(s). Contact lenses should be removed prior to and for at least 30 minutes after the administration of MIEBO. 2.2 Administration Instructions Step 1. Remove the cap from eye drop bottle. Step 2. Holding the bottle upright, gently squeeze the bottle. Step 3. While squeezing, turn the bottle upside …

5 WARNINGS AND PRECAUTIONS 5.1 Use with Contact Lenses MIEBO should not be administered while wearing contact lenses. Advise patients that contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO.

4 CONTRAINDICATIONS Hypersensitivity. ( 4.1 ) 4.1 Hypersensitivity MIEBO is contraindicated in patients with a history of hypersensitivity reaction to perfluorohexyloctane [see Adverse Reactions ( 6.1 )] .

Perfluorohexyloctane is a prescription medication. You will need a valid prescription from a licensed healthcare provider.

Similar Drops Products

Glycerin, Naphazoline Hcl

Cyclopentolate Hydrochloride

Omidenepag Isopropyl

Ddorzolamide Hydrochloride Timolol Maleate

Naphazoline Hydrochloride And Pheniramine …

Propylene Glycol

Browse all Drops products →

References & Data Sources

• DailyMed — Perfluorohexyloctane drug label (National Library of Medicine)
• openFDA — Perfluorohexyloctane label data (U.S. Food & Drug Administration)
• NDC Directory — Perfluorohexyloctane (FDA National Drug Code)

إخلاء المسؤولية الطبية

المعلومات الواردة في هذه الصفحة مخصصة للأغراض التعليمية فقط ولا ينبغي استخدامها بديلًا عن المشورة الطبية المتخصصة أو التشخيص أو العلاج.

استشر دائمًا طبيبك أو أي مقدم رعاية صحية مؤهل بشأن أي أسئلة تتعلق بحالة طبية أو دواء.

مصادر البيانات: DailyMed (NLM), openFDA, MFDS